Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

A1340000

Atenolol

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C14H22N2O3
Numero CAS:
29122-68-7
Peso molecolare:
266.34
Numero CE:
249-451-7
Numero MDL:
MFCD00057645
Codice UNSPSC:
41116107
ID PubChem:
329770360
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

atenolol

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
METKIMKYRPQLGS-UHFFFAOYSA-N

Informazioni sul gene

human ... ADRB1(153)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Atenolol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

1044403

Atenolol, United States Pharmacopeia (USP) Reference Standard

Y0001089

Atenolol for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1909

Atenolol, Pharmaceutical Secondary Standard; Certified Reference Material

BP370

Atenolol impurity standard, British Pharmacopoeia (BP) Reference Standard

BP492

Atenolol, British Pharmacopoeia (BP) Reference Standard

1044367

Atenolol Related Compound F, United States Pharmacopeia (USP) Reference Standard

1044265

Atenolol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044254

Atenolol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1044276

Atenolol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1044298

Atenolol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1044287

Atenolol Related Compound D, United States Pharmacopeia (USP) Reference Standard

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
H Sakurai et al.
Japanese circulation journal, 64(11), 893-896 (2000-12-08)
Cardiogenic shock developed in a 72-year-old Japanese woman during combination therapy with verapamil and atenolol for recurrent supraventricular arrhythmia. She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome. Despite of the high-dose catecholamines and counterpulsation, she progressively deteriorated. Bolus administration
Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity.
Sonia A Tabacova et al.
Reproductive toxicology (Elmsford, N.Y.), 16(1), 1-7 (2002-04-06)
Laura M Kuyper et al.
The Canadian journal of cardiology, 30(5 Suppl), S47-S53 (2014-04-23)
Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We
Visualizza tutti i documenti correlati

Articoli

TLC Silica Gel 60 G Plates with Gypsum

TLC plates, with silica gel, gypsum as binder, International Pharmacopoeia compliant, for identification of Atenolol and Chlorthalidone in tablets

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.